Compare AbbVie Inc (ABBV) vs H2O America (HTO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs H2O America — how do they compare? AbbVie Inc trades at $253.86 (market cap $449.91B), while H2O America trades at $61.6 (market cap $2.58B). The key difference: AbbVie Inc is far larger — about 174.4× H2O America's market cap, and H2O America pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| ABBV | HTO | |
|---|---|---|
Market Cap | $449.91B | $2.58B |
Sector | Health | Technology |
52-Week High | $261.07 | $62.42 |
52-Week Low | $184.85 | $44.44 |
Enterprise Value | $513.38B | $4.31B |
Dividend Yield | 2.72% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
HTO trades at $61.21, down 1.94% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $61.33. The company reported Q1 2026 EPS of $0.50, beating expectations, and maintains strong fundamentals with a 12.87% net income margin. Recent news highlights executive appointments and institutional investments, reinforcing positive sentiment.
The stock presents a balanced opportunity with steady earnings growth and a reliable dividend, but faces risks from high RSI levels indicating overbought conditions and substantial capital expenditures. Analyst consensus is strongly bullish with 80% buy ratings, though investors should monitor execution of growth initiatives and sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →
